| UniProt/SwissProt ID: | KPYM_HUMAN |
| Description: | pyruvate kinase, muscle [Source:HGNC Symbol;Acc:9021] |
| Location: | chr15 q23 |
| Node attribute: | substrate |
| Phosphorylation site |
| Position | PhosphoPeptide | Catalytic kinase | Source |
|---|---|---|---|
| S287 | EILEAsDGIMV | PK | PhosphoSitePlus |
| Y390 | AEAAIyHLQLF | HPRD; phosphoELM | |
| Y83 | HGTHEyHAETI | phosphoELM | |
| S269 | NIKIIsKIENH | PK | PhosphoSitePlus |
| S100 | TESFAsDPILY | PK | PhosphoSitePlus |
| S127 | GLIKGsGTAEV | PK | PhosphoSitePlus |
| Y466 | RQAHLyRGIFP | PK_C | PhosphoSitePlus |
| Y161 | ILWLDyKNICK | PK | PhosphoSitePlus |
| S243 | DMVFAsFIRKA | PK | PhosphoSitePlus |
| T87 | EYHAEtIKNVR | PK | PhosphoSitePlus |
| T129 | IKGSGtAEVEL | HPRD | |
| T80 | NFSHGtHEYHA | PK | PhosphoSitePlus |
| T50 | TGIICtIGPAS | PK | PhosphoSitePlus |
| T45 | ITARNtGIICT | HPRD; phosphoELM | |
| T328 | PVICAtQMLES | HPRD; phosphoELM | |
| T195 | ADFLVtEVENG | PK | PhosphoSitePlus |
| T60 | SRSVEtLKEMI | PK | PhosphoSitePlus |
| Y370 | TAKGDyPLEAV | PK | PhosphoSitePlus |
| S362 | DCIMLsGETAK | PK | PhosphoSitePlus |
| T41 | DSPPItARNTG | PK | PhosphoSitePlus |
| S37 | RLDIDsPPITA | PhosphoSitePlus; HPRD; phosphoELM; SysPTM | |
| S249 | FIRKAsDVHEV | PK | PhosphoSitePlus |
| T328 | PVICAtQMLES | PK | PhosphoSitePlus |
| T129 | IKGSGtAEVEL | PK | PhosphoSitePlus |
| S406 | LAPITsDPTEA | HPRD | |
| Y83 | HGTHEyHAETI | PK | PhosphoSitePlus |
| S287 | EILEAsDGIMV | HPRD | |
| S172 | VVEVGsKIYVD | HPRD | |
| T45 | ITARNtGIICT | PK | PhosphoSitePlus |
| S222 | DLPAVsEKDIQ | PK | PhosphoSitePlus |
| S172 | VVEVGsKIYVD | PK | PhosphoSitePlus |
| S57 | GPASRsVETLK | HPRD | |
| Y175 | VGSKIyVDDGL | PK | PhosphoSitePlus |
| Y148 | TLDNAyMEKCD | PK | PhosphoSitePlus |
| S77 | ARLNFsHGTHE | PK | PhosphoSitePlus |
| S97 | RTATEsFASDP | PK | PhosphoSitePlus |
| Y105 | SDPILyRPVAV | PK | PhosphoSitePlus |
| S57 | GPASRsVETLK | PK | PhosphoSitePlus |
| T93 | IKNVRtATESF | PK | PhosphoSitePlus |
| Y390 | AEAAIyHLQLF | PK | PhosphoSitePlus |
| T405 | RLAPItSDPTE | HPRD | |
| Y105 | SDPILyRPVAV | HPRD; phosphoELM | |
| T454 | PIIAVtRNPQT | PK_C | PhosphoSitePlus |
| Dephosphorylation site |
| KPYM_HUMAN do not have dephosphorylation site. |
| Mutation site |
| Ensembl ID | Variation | Source | Cancer name | Pubmed |
|---|---|---|---|---|
| ENSP00000373745 | *532R | COSMIC | Breast Cancer | 20668451 | ENSP00000320171 | *532R | COSMIC | Breast Cancer | 20668451 | ENSP00000455736 | *532R | COSMIC | Breast Cancer | 20668451 | ENSP00000334983 | *532R | COSMIC | Breast Cancer | 20668451 | ENSP00000456970 | *532R | COSMIC | Breast Cancer | 20668451 | ENSP00000455901 | *532R | COSMIC | Breast Cancer | 20668451 |
| Differential expressed protein |
| Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
|---|---|---|---|---|---|---|
| ENSP00000334983 | breast ductal carcinoma | Normal vs. Cancer | tissue | Up | 3.7 | 14625848 | ENSP00000334983 | Gastric Cancer | Metastasis | cell line | Down | 0.51 | 17022644 | ENSP00000334983 | Uterine Cancer | Normal vs. Cancer | tissue | Up | 17902640 | ENSP00000334983 | Ovarian Cancer | Treatment (cisplatin-sensitive vs. cisplatin-resistant) | cell line | Up | 1.9 | 16319398 | ENSP00000334983 | Leukemia | Normal vs. Cancer | cell line | Down | 0.43 | 17022645 | ENSP00000334983 | Leukemia | Normal vs. Cancer | cell line | Down | 0.38 | 17022645 | ENSP00000334983 | Lung Cancer | Treatment (none vs. FK228 treatment) | cell line | Down | 18549279 | ENSP00000334983 | Oral Premalignant Lesions | Normal vs. Cancer | tissue | Up | 1 | 19072117 | ENSP00000334983 | Oral Premalignant Lesions | Normal vs. Cancer | tissue | Up | 1.4 | 19072117 | ENSP00000334983 | Oral Premalignant Lesions | Normal vs. Cancer | tissue | Up | 1.3 | 19072117 | ENSP00000334983 | Oral Premalignant Lesions | Normal vs. Cancer | tissue | Up | 1.7 | 19072117 | ENSP00000334983 | Oral Premalignant Lesions | Normal vs. Cancer | tissue | Up | 1.1 | 19072117 | ENSP00000334983 | Oral Premalignant Lesions | Normal vs. Cancer | tissue | Up | 1.1 | 19072117 | ENSP00000334983 | Breast Cancer | Normal vs. Cancer | cell line | Up | 1500 | 14997480 | ENSP00000334983 | Breast Cancer | Normal vs. Cancer | cell line | Up | 320 | 14997480 | ENSP00000334983 | Melanoma | Treatment (none vs. metastasis suppressor 1 (BRMS1) overEXPressed) | cell line | Up | 3.3 | 17854218 | ENSP00000334983 | Hepatocellular Carcinoma | Cancer vs. Cancer (HCC vs. HuCCA) | cell line | Up | 20069059 | ENSP00000334983 | Neoplasms by Histologic Type | Cancer vs. Cancer | cell line | Up | 15750928 | ENSP00000334983 | Neoplasms by Histologic Type | Cancer vs. Cancer | cell line | Up | 15750928 | ENSP00000334983 | Lung Cancer | Cancer vs. Cancer | cell line | Down | 17284061 | ENSP00000334983 | Non-small cell lung carcinoma | Treatment (none vs CIGB-300 treatment) | cell line | Down | 0.1 | 20804217 | ENSP00000334983 | Gastric Cancer | Metastasis | cell line | Down | 0.51 | 17022644 | ENSP00000334983 | Gastric Cancer | Normal vs. Cancer | tissue | Up | 16 | 18723843 | ENSP00000334983 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.56 | 20052998 | ENSP00000334983 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.65 | 20052998 | ENSP00000334983 | Breast Cancer | Metastasis | cell line | Up | 1.1 | 20052998 | ENSP00000334983 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.73 | 20543960 | ENSP00000334983 | Breast Cancer | Cancer vs. Cancer (Non-TNBC vs. TNBC) | cell line | Up | 20596302 | ENSP00000334983 | Oral Cancer | Normal vs. Cancer | tissue | Up | 5.2 | 19691830 | ENSP00000334983 | Neoplasms by Histologic Type | Treatment (none vs. SB203580 treatment 21 hour) | cell line | Down | 0.4 | 15169874 | ENSP00000334983 | Renal Cancer | Normal vs. Cancer | tissue | Up | 1.1-20.8 | 12923786 | ENSP00000334983 | Renal Cancer | Normal vs. Cancer | tissue | Up | 2.1-3.5 | 12923786 | ENSP00000334983 | Renal Cancer | Normal vs. Cancer | tissue | Up | 2.4-14.8 | 12923786 | ENSP00000334983 | Renal Cancer | Normal vs. Cancer | tissue | Up | 19164279 | ENSP00000334983 | Melanoma | Treatment (none vs. kojic acid treatment) | cell line | Up | 2.1 | 18630942 | ENSP00000334983 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Up | 1.4 | 18973835 | ENSP00000334983 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Up | 1.3 | 18973835 | ENSP00000334983 | Ovarian Cancer | Treatment (Paclitaxel-sensitive vs. Paclitaxel-resistant) | cell line | Up | 1.4 | 19714814 | ENSP00000334983 | Pancreatic Cancer | Normal vs. Cancer | tissue | Up | 3 | 15526344 | ENSP00000334983 | Gastric Cancer | Treatment (none vs. drug-resistant) | cell line | Down | 0.67 | 20625496 | ENSP00000334983 | Uterine Cancer | Treatment(21% oxygen vs. 1% oxygen (mild hypoxia) supplemented ) | cell line | Up | 19541378 | ENSP00000334983 | Uterine Cancer | Treatment(21% oxygen vs. 0% oxygen (mild hypoxia) supplemented ) | cell line | Up | 19541378 | ENSP00000334983 | Head and Neck Cancer | Treatment(21% oxygen vs. 1% oxygen (mild hypoxia) supplemented ) | cell line | Up | 19541378 | ENSP00000334983 | Head and Neck Cancer | Treatment(21% oxygen vs 0% oxygen (mild hypoxia) supplemented ) | cell line | Up | 19541378 |
| Hyperphosphorylation site |
| KPYM_HUMAN do not have hyperphosphorylation site. |
| Direct Interaction Pair |
| Source | Target | Relationship | Resource |
|---|---|---|---|
| FAK2_HUMAN | KPYM_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| SCYL2_HUMAN | KPYM_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| LYN_HUMAN | KPYM_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| CDK4_HUMAN | KPYM_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| FGFR2_HUMAN | KPYM_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| WEE1_HUMAN | KPYM_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| YES_HUMAN | KPYM_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| STK3_HUMAN | KPYM_HUMAN | kinase -> substrate | Robert H Newman (2013) |
| Function Annotation |
| KEGG Pathway |
| KPYM_HUMAN is not in KEGG pathway. |
| Gene Ontology |
| GO ID | GO_Term | Evidence | Ontology |
|---|---|---|---|
| GO:0070062 | extracellular vesicular exosome | IDA | cellular_component |
| GO:0005634 | nucleus | IDA | cellular_component |
| GO:0005515 | protein binding | IEA | molecular_function |
| GO:0006006 | glucose metabolic process | TAS | biological_process |
| GO:0000287 | magnesium ion binding | IEA | molecular_function |
| GO:0005515 | protein binding | IPI | molecular_function |
| GO:0003824 | catalytic activity | IEA | molecular_function |
| GO:0005829 | cytosol | NAS | cellular_component |
| GO:0005975 | carbohydrate metabolic process | TAS | biological_process |
| GO:0005737 | cytoplasm | IDA | cellular_component |
| GO:0004743 | pyruvate kinase activity | IEA | molecular_function |
| GO:0044281 | small molecule metabolic process | TAS | biological_process |
| GO:0005886 | plasma membrane | IDA | cellular_component |
| GO:0005524 | ATP binding | IEA | molecular_function |
| GO:0006096 | glycolysis | IEA | biological_process |
| GO:0012501 | programmed cell death | IDA | biological_process |
| GO:0005739 | mitochondrion | IEA | cellular_component |
| GO:0030955 | potassium ion binding | IEA | molecular_function |